stockrowVericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024.
- Revenue
- +26.5%
- EPS
- +180.0%
- Free cash flow
- −19.4%
Quarter to September 2026, against a year earlier
Follow VCEL
Alert me
Vericel Corporation (VCEL) Revenue growth
Vericel Corporation's revenue growth over the twelve months to 30 September 2026 was 25.3%, up 8.8 percentage points from fiscal 2025 (16.5%). Over the past ten years it has ranged from 5.24% (fiscal 2022) to 77.7% (fiscal 2015); the current reading is higher than 36% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 16.5% | (3.65) |
| FY2024 | 20.1% | (0.07) |
| FY2023 | 20.2% | 14.93 |
| FY2022 | 5.24% | (20.53) |
| FY2021 | 25.8% | 20.40 |
| FY2020 | 5.37% | (24.34) |
| FY2019 | 29.7% | (12.42) |
| FY2018 | 42.1% | 24.59 |
| FY2017 | 17.5% | 11.26 |
| FY2016 | 6.28% | (71.41) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 26.5% | 3.99 |
| Jun 2026 | 22.5% | (7.61) |
| Mar 2026 | 30.1% | 6.82 |
| Dec 2025 | 23.3% | 6.69 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| BHVN Biohaven Ltd. compare | 425.2% |
| PVLA Palvella Therapeutics, Inc. compare | 146.7% |
| VCEL Vericel Corporation | 25.3% |
| AUPH Aurinia Pharmaceuticals Inc compare | 21.0% |
| IMNM Immunome, Inc. compare | 16.7% |
| ADMA ADMA Biologics Inc compare | 6.26% |
| CLDX Celldex Therapeutics, Inc. compare | −88.3% |
| PHVS Pharvaris N.V. compare | — |
| VERA Vera Therapeutics, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on VCEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement